A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
Abstract The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential bindi...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6280e71ffa694c31a509b1afcf87bff2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|